Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Future Developments - Ep 3

Episode 3 October 21, 2021 00:17:57
Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Future Developments - Ep 3
COR2ED Medical Education
Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Future Developments - Ep 3
/

Show Notes

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.

In this third episode, the experts turn their focus to earlier stage disease and consider how lessons learnt in the treatment of metastatic disease can be applied in the neo adjuvant setting for colorectal cancer by discussing data from the FOXTROT and NICHE trials and the adjuvant setting for gastric cancer by discussing data from CheckMate 577.  Finally, the experts consider new promising data on targeting KRAS compared to the MEK and the ERK inhibitors.

Other Episodes

Episode 1

March 08, 2022 00:38:59
Episode Cover

Prostate Cancer Highlights from ASCO GU 2022

COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Prostate Cancer Highlights from ASCO GU 2022’ in this GU CONNECT podcast. In this podcast, the experts review data from a number of key plenary sessions from ASCO GU 2022 and discuss potential implications for clinical practice. The ARASENS trial is covered first which looked at triplet therapy in the form of ADT plus docetaxel and darolutamide in patients with metastatic castration sensitive prostate cancer (mCSPC). Discussion then moves to two trials investigating the combination of abiraterone acetate with PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) patients with and without homologous recombination repair (HRR) mutations: the PROpel trial with olaparib and the MAGNITUDE trial with rucaparib.  Neal and Alicia also discuss a fascinating presentation by Dr. Daniel Spratt which looked at digitising histopathology slides and using Artificial Intelligence (AI) to inform on the likelihood of disease progression and whether or not patients needed androgen deprivation therapy (ADT) Finally, Alicia discusses a number of posters which she felt made an impact, including one on PSA responses in the TITAN and SPARTAN trials and a secondary analysis from the VISION trial looking at treatment related adverse events, amongst others.  ...

Listen

Episode 1

July 05, 2022 00:21:56
Episode Cover

Timing of ARSI and taxanes for mCSPC

COR2ED Medical Education: Dr. Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Timing of ARSI and taxanes for mCSPC’ in this GU CONNECT podcast. In this podcast, the experts reflect on how the treatment landscape for mCSPC has evolved over the past 7 years resulting in treatment intensification with ADT plus docetaxel following the CHAARTED and STAMPEDE studies and then more recently the use of ADT and androgen receptor inhibitors including abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET).  This has further evolved with the recent reporting of the PEACE 1 and ARASENS trials which demonstrated a survival benefit with triplet therapy with abiraterone and darolutamide respectively, being used in combination with ADT and docetaxel. The experts discuss the importance of balancing benefit against risk for their mCSPC patients but state that the triplet therapies appear to be well tolerated in both the PEACE 1 and ARASENS trials. They provide their views, Neal as a urologist and Tanya as a medical oncologist, on the things to consider when making treatment decisions for these patients such as comorbidities, age, performance status, de novo versus recurrent disease, amongst others. They finish by concluding that treatment intensification should be implemented as standard of care for mCSPC patients to enable patients to have as many treatments with different mechanisms of action as early as possible in their treatment journey.  ...

Listen

Episode 3

July 29, 2021 00:18:39
Episode Cover

Women & Girls Bleed Too: Managing Bleeding Disorders - Episode 3

In this third episode of the podcast series Women and Girls Bleed Too, Advanced Nurse Practitioner Debra Pollard (Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK) is joined by Haematologist Dr. Michelle Lavin (RCSI and National Coagulation Centre, St James’ Hospital, Dublin, Ireland). They talk about the impact a bleeding disorder can have on the lives on women and girls and how these patients can and should be supported in first- and second-line care. When thinking about management, many healthcare providers will first consider medical treatment. Dr. Lavin gives a brief overview of the first-line treatment options for women and girls with bleeding symptoms. However, the speakers stress that the management of these patients goes beyond medical treatment options alone. They provide practical tips and recommendations for first-line healthcare professionals when they treat a patient with a bleeding disorder. As many bleeding disorders are hereditary diseases, a diagnosis not only has impact on the patient, but on their family as well. A bleeding disorder also impacts family planning, pregnancy, and quality of life. Medical and psychological support is essential throughout life. Finally, Michelle Lavin and Debra Pollard discuss some important topics for first-line healthcare providers to be aware of when they have a woman with a bleeding disorder in their practice, including the impact of a bleeding disorder on any medical invention, such as surgery, dental procedures or infertility treatment, but also on the use of pain medication. ...

Listen